Prosecution Insights
Last updated: September 17, 2026
Application No. 18/001,173

METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES

Non-Final OA §102§103§112
Filed
Dec 08, 2022
Priority
Jun 09, 2020 — EU 20178980.7 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Heidelberg Pharma Research GmbH
OA Round
2 (Non-Final)
61%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
456 granted / 747 resolved
+1.0% vs TC avg
Strong +33% interview lift
Without
With
+32.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
76 currently pending
Career history
799
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
16.9%
-23.1% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 747 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim Status Claims 1-20 are pending. Claim 20 has been added. Claims 1 and 14 have been amended. In the response to the restriction requirement, Applicants elected Group I and compound 22a. Applicants elected species (i.e. compound 22a) was deemed to be free of the prior art. Claim Rejections - 35 USC § 112 The rejection of claims 1-5 and 7-10 under 35 USC 112(b) is withdrawn in view of the amendments to the claims. Improper Markush Claims 1-11 and 20 are rejected under the judicially created basis of improper Markush group of alternatives. See 76 Fed. Reg. 7164-7166 (Feb. 9, 2011); In re Harnish, 631 F.2d 716m 721-22 (CCPA 1980); Ex parte Hosuzmi, 3 USPQ2d 1059m 1060 (Bd. Pat. App. & Int. 1984). For a Markush grouping to be proper the species of the Markush group must share a ‘‘single structural similarity” and must share a common use. Members of a Markush group share a "single structural similarity" when they belong to the same recognized physical or chemical class or to the same art recognized class. Here, the claimed compounds do not share a "single structural similarity.” The template portion of the claimed compound contains different molecules that do not belong to the same recognized physical or chemical class and do not belong to the same art recognized class. For instance, the structural requirements of SH (variable Z) are completely different from S-trityl. Similarly, variable Y comprises unrelated molecules (i.e. these molecules do not belong to the same art recognized class). Variable B comprises an a-amino acid and a b-amino acid backbone, which, once again, do not belong to the same art recognized class. The different compounds encompassed by the claims do not belong to the same recognized physical or chemical class and do not belong to the same art recognized class. Response to Arguments Applicant’s arguments filed on 8/10/2026 have been fully considered but they are not persuasive. Applicant argues that “[a]ccording to In re Harnisch, the structure of the compound as a whole must be considered for structural similarity with each listed substituent (rather than just comparing the substituents to each other in each group). The common structural features are that the amanitin precursor compound includes a cyclic moiety containing an indole ring, the cyclic moiety including a specific number of amino acids, and two lower alkyl linkers. Also, all compounds regardless of substituents have the common use of being adapted to form amanitin toxin compounds. Thus, according to In re Harnisch the present claims are directed to proper Markush Groups”. Applicant’s arguments are not persuasive because the instantly claimed compounds do not share a common structure. Claim 1 recites “X is either (-(-indole-S-) or (-S-indole-)-) with the indole being an unsubstituted or hydroxyl-, halogen-, halogenated carbon-, alkynyl-, olefin-, cyano-, protected carboxylate and/or carboxyamide-substituted indole, wherein optionally the sulphur atom of X can be subsequently oxidized”. A substituted indole is different than a substituted indole. Therefore, in contrary to Applicant’s arguments, the instantly claimed compounds do not share a common structure. With respect to Applicant’s arguments regarding “a common use”, The MPEP 2117 states that “[A] Markush claim may be rejected under judicially approved "improper Markush grouping" principles when the claim contains an improper grouping of alternatively useable members. A Markush claim contains an "improper Markush grouping" if either: (1) the members of the Markush group do not share a "single structural similarity" or (2) the members do not share a common use. Supplementary Guidelines at 7166 (citing In re Harnisch, 631 F.2d 716, 721-22, 206 USPQ 300, 305 (CCPA 1980))”. In the instant case, as discussed above, the members of the Markush group do not share a "single structural similarity". Therefore, the claims are properly rejected under the judicially created basis of improper Markush group of alternatives. For the reasons stated above the rejection is maintained. Claim Rejections - 35 USC § 102 The rejection of claims 1-4 and 7-10 under 35 U.S.C. 102(a)(1) as being anticipated by Lokey et al. is withdrawn in view of Applicant’s arguments. Claim Rejections - 35 USC § 103 The rejection of claims 1-5 and 7-10 under 35 U.S.C. 103 as being unpatentable over Lokey et al. is withdrawn in view of Applicant’s arguments. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Dec 08, 2022
Application Filed
Apr 10, 2026
Non-Final Rejection mailed — §102, §103, §112
Aug 10, 2026
Response Filed
Sep 03, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735464
C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
6y 10m to grant Granted Sep 15, 2026
Patent 12735463
PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS
5y 3m to grant Granted Sep 15, 2026
Patent 12735454
PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF
3y 9m to grant Granted Sep 15, 2026
Patent 12735452
ADHESIVE PEPTIDES
3y 3m to grant Granted Sep 15, 2026
Patent 12698312
JNK3 INHIBITORY PEPTIDES
3y 8m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+32.7%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 747 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month